Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 19/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12086284 | 0.86 | RAB9A (0.42) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL12198759 | 0.84 | CHRM1 (0.39) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL12086312 | 0.84 | CHRM1 (0.48) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL12988771 | 0.82 | CHRM1 (0.37) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL12199273 | 0.81 | CHRM1 (0.42) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL13058790 | 0.80 | CHRM1 (0.38) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL12086282 | 0.80 | CHRM1 (0.39) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL13034555 | 0.78 | GAA (0.33) | HCRTR2 | |
| SCHEMBL12086290 | 0.77 | CHRM1 (0.42) | CHRM1CHRM2CHRM3CHRM4CHRM5 | |
| SCHEMBL12086318 | 0.77 | CHRM1 (0.44) | CHRM1CHRM2CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-20100311720-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311720-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM4 | CHRM1 9/4885CHRM2 2/4885CHRM3 1/4885 |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | CHRM1 6/4885CHRM2 2/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.